Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(3.95)
# 668
Out of 4,996 analysts
119
Total ratings
49.59%
Success rate
11.17%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMUX Immunic | Reiterates: Buy | $10 | $0.94 | +964.85% | 5 | Sep 26, 2025 | |
| ADVM Adverum Biotechnologies | Reiterates: Buy | $30 | $4.51 | +565.19% | 7 | Sep 23, 2025 | |
| FBLG FibroBiologics | Reiterates: Buy | $10 | $0.57 | +1,643.38% | 6 | Sep 12, 2025 | |
| MLYS Mineralys Therapeutics | Reiterates: Buy | $42 | $39.99 | +5.03% | 11 | Sep 8, 2025 | |
| KOD Kodiak Sciences | Maintains: Neutral | $3 → $5 | $15.80 | -68.35% | 5 | Aug 18, 2025 | |
| DMAC DiaMedica Therapeutics | Reiterates: Buy | $12 | $6.94 | +72.91% | 7 | Aug 15, 2025 | |
| LYRA Lyra Therapeutics | Reiterates: Neutral | $16 | $6.47 | +147.30% | 9 | Aug 14, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Buy | $48 → $56 | $42.03 | +33.24% | 7 | Aug 1, 2025 | |
| IRD Opus Genetics | Reiterates: Buy | $8 | $1.82 | +339.56% | 4 | Jun 27, 2025 | |
| ARDX Ardelyx | Assumes: Buy | $10 | $5.54 | +80.51% | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $11.78 | +69.78% | 10 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $2.74 | +191.97% | 1 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $72 | $56.29 | +27.91% | 1 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $5.07 | +97.24% | 13 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $20.04 | +49.70% | 3 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $11.56 | +176.82% | 3 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $3.41 | -41.35% | 7 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $8.39 | +329.08% | 18 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $358.90 | -92.20% | 1 | Aug 22, 2023 |
Immunic
Sep 26, 2025
Reiterates: Buy
Price Target: $10
Current: $0.94
Upside: +964.85%
Adverum Biotechnologies
Sep 23, 2025
Reiterates: Buy
Price Target: $30
Current: $4.51
Upside: +565.19%
FibroBiologics
Sep 12, 2025
Reiterates: Buy
Price Target: $10
Current: $0.57
Upside: +1,643.38%
Mineralys Therapeutics
Sep 8, 2025
Reiterates: Buy
Price Target: $42
Current: $39.99
Upside: +5.03%
Kodiak Sciences
Aug 18, 2025
Maintains: Neutral
Price Target: $3 → $5
Current: $15.80
Upside: -68.35%
DiaMedica Therapeutics
Aug 15, 2025
Reiterates: Buy
Price Target: $12
Current: $6.94
Upside: +72.91%
Lyra Therapeutics
Aug 14, 2025
Reiterates: Neutral
Price Target: $16
Current: $6.47
Upside: +147.30%
LENZ Therapeutics
Aug 1, 2025
Maintains: Buy
Price Target: $48 → $56
Current: $42.03
Upside: +33.24%
Opus Genetics
Jun 27, 2025
Reiterates: Buy
Price Target: $8
Current: $1.82
Upside: +339.56%
Ardelyx
Jun 18, 2025
Assumes: Buy
Price Target: $10
Current: $5.54
Upside: +80.51%
Jun 9, 2025
Reiterates: Buy
Price Target: $20
Current: $11.78
Upside: +69.78%
Jun 4, 2025
Assumes: Buy
Price Target: $8
Current: $2.74
Upside: +191.97%
May 27, 2025
Assumes: Buy
Price Target: $72
Current: $56.29
Upside: +27.91%
May 19, 2025
Reiterates: Buy
Price Target: $10
Current: $5.07
Upside: +97.24%
May 16, 2025
Reiterates: Buy
Price Target: $30
Current: $20.04
Upside: +49.70%
May 12, 2025
Reiterates: Buy
Price Target: $32
Current: $11.56
Upside: +176.82%
Mar 25, 2025
Downgrades: Neutral
Price Target: $12 → $2
Current: $3.41
Upside: -41.35%
Mar 3, 2025
Reiterates: Buy
Price Target: $36
Current: $8.39
Upside: +329.08%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $358.90
Upside: -92.20%